Dr. Danae Delivanis on Pembrolizumab and Nivolumab in Metastatic Melanoma
Danae Delivanis, MD, endocrinologist, Mayo Clinic, on the use of pembrolizumab and nivolumab in the treatment of metastatic melanoma.
Danae Delivanis, MD, endocrinologist, Mayo Clinic, on the use of pembrolizumab and nivolumab in the treatment of metastatic melanoma. Delivanis says while the two treatments have improved the overall survival of patients with metastatic melanoma by 7 months, clinicians should be aware of the thyroiditis and hypothyroidism that can occur as a side effect of the treatments.
In a retrospective study conducted by Delvanis in 94 patients on both treatments,she says there were no differences in occurrence between male and female patients. The median age of participants in the study was 58 years old and the onset of the side effects were about 6 weeks since the tart of treatment.
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
